UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.
View/ Open
Date
2018-01Author
Hanna, GG
Murray, L
Patel, R
Jain, S
Aitken, KL
Franks, KN
van As, N
Tree, A
Hatfield, P
Harrow, S
McDonald, F
Ahmed, M
Saran, FH
Webster, GJ
Khoo, V
Landau, D
Eaton, DJ
Hawkins, MA
Type
Journal Article
Metadata
Show full item recordAbstract
Six UK studies investigating stereotactic ablative radiotherapy (SABR) are currently open. Many of these involve the treatment of oligometastatic disease at different locations in the body. Members of all the trial management groups collaborated to generate a consensus document on appropriate organ at risk dose constraints. Values from existing but older reviews were updated using data from current studies. It is hoped that this unified approach will facilitate standardised implementation of SABR across the UK and will allow meaningful toxicity comparisons between SABR studies and internationally.
Collections
Subject
Humans
Radiosurgery
Consensus
Guidelines as Topic
United Kingdom
Research team
Lung Radiotherapy
Stereotactic and Precision Body Radiotherapy
Language
eng
Date accepted
2017-09-18
License start date
2018-01
Citation
Clinical oncology (Royal College of Radiologists (Great Britain)), 2018, 30 (1), pp. 5 - 14